We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...
The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...
Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia ...
With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next.
Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...
Pfizer has appointed former Patrizia Cavazzoni, MD, former director of the FDA's Center for Drug Evaluation and Research, as its new chief medical officer, Bloomberg reported Feb. 24. Dr. Cavazzoni, ...
Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback